 Yes. So prior to the approval of Avakit in 2023, which is the first FDA-approved treatment for intelligent systemic mastocytosis, prior to that, we used to use a wide variety of medications, mostly symptom-driven medications. Now, even then, in that scenario, too, they would not completely...